The number of global cases of COVID-19 crossed 300 million on Thursday night, according to data compiled by Johns Hopkins University.

The U.S. continues to have the most cases in the world -- as it has all pandemic -- with over 58 million cases. India (35 million), Brazil (22 million), the U.K. (14 million) and France (11 million) round out the top 5 countries by total cases.

Global cases crossed 200 million on Aug. 4, 2021, and 100 million on Jan. 26, 2021, according to JHU.

With many people now experiencing second bouts of the virus, it's unclear how many total people have been infected globally.

Chicago Public Schools, the nation's third largest school district, canceled instruction on Friday for the third day in a row amid an impasse over in-person learning.

Classes were first canceled Wednesday, and then again on Thursday, after a majority of the Chicago Teachers Union's membership voted this week in favor of remote learning during a surge in COVID-19 cases.

The district said Thursday evening that all classes will be canceled on Friday, though some schools may be able to offer in-person activities for students.

"Our schools are the best, safest place for students to be during this pandemic, and we are working tirelessly to get everyone back in class every day," Pedro Martinez, head of the school district, said in a letter to families, noting that they are continuing to work with the union "to resolve this situation."

The teacher's union is calling for more robust school COVID-19 testing and contact tracing.

Johnson & Johnson's single-shot COVID-19 vaccine offers lower initial efficacy compared to Pfizer's and Moderna's, but protection against breakthrough infection remains more stable over time, according to a new study sponsored by the pharmaceutical company.

The study found that the J&J vaccine was 74% effective against breakthrough infection in the weeks following the shot. This level of protection held steady over the next three months and started waning after the fourth month.

The Pfizer and Moderna vaccines, meanwhile, were 88% and 92% effective, respectively, against breakthrough infection in the weeks following the second dose, the study found. This level of protection started waning after the second month, falling progressively over six months.

Protection against severe illness remained more stable over time for all three vaccines.

The analysis, which has not been peer-reviewed, looked at data from 168 million people between Jan. 1 and Sept. 7 of last year. It covers a period of alpha and delta variant dominance, but the results could change now that the omicron variant is also present.

The data supports current guidance from the Centers for Disease Control and Prevention for booster shots after two months for the J&J vaccine to bring initial efficacy higher, and booster shots for Pfizer and Moderna vaccines after five and six months, respectively, to boost efficacy after a period of waning.

-ABC News' Sony Salzman

COVID-19 vaccines dramatically reduce the risk of severe illness and death from the virus, according to a new study from the Centers for Disease Control and Prevention published Thursday.

The study looked at 1.2 million fully vaccinated adults who received either two shots of the Pfizer-BioNTech or Moderna vaccines or one shot of the Johnson & Johnson vaccine.

Just 0.18% of patients had breakthrough COVID-19 infections, and 0.015% developed serious illness that led to hospitalization, ICU admission, mechanical ventilation, intubation or death.

The small portion of people who did become seriously sick or die of COVID-19 after being vaccinated were primarily older adults, immunocompromised people or those living with multiple underlying medical conditions.

The study was conducted before the emergence of the omicron variant, which appears to more easily evade --- at least partially -- the protection offered by vaccines.

-ABC News' Sony Salzman

The White House said Wednesday it is confident it can deliver millions of rapid COVID-19 tests to Americans in January.

Last month, the administration announced it was planning to distribute 500 million free at-home rapid tests across the country to combat the surging omicron variant.

However, a website has yet to be launched where people can order the tests and the U.S. is currently producing less than half of the tests needed -- 200 million a month.

During a virtual briefing, Jeff Zients, the White House Coronavirus Response Coordinator, said the government not only has the capacity to deliver 500 million tests, but it also won't dip into the current supply on pharmacy shelves.

"With all the companies that now have been authorized, there’s the capacity for the U.S. government to purchase the 500 million now and not disrupt, or in any way cannibalize, the tests that are on pharmacy shelves and on websites and used and other settings," he said.

-ABC News' Cheyenne Haslett